RANI RANI THERAPEUTICS HLDGS INC

Rani Therapeutics to Participate in Upcoming Investor Conferences

Rani Therapeutics to Participate in Upcoming Investor Conferences

SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s management team will participate in three upcoming conferences. These conferences include:

UBS Global Healthcare Conference

Location: Terranea Resort, Rancho Palos Verdes, CA

Date: Thursday, November 14, 2024 at 10:15am PT

Format: Fireside Chat and 1x1 Meetings

Stifel Healthcare Conference

Location: Lotte New York Palace Hotel, New York, NY

Date: Monday, November 18, 2024 at 4:10pm ET

Format: Fireside Chat and 1x1 Meetings

7th Annual Evercore ISI HealthCONx Conference

Location: The Loews Coral Gables Hotel, Coral Gables, FL

Date: Wednesday, December 4, 2024 at 12:55pm ET

Format: Fireside Chat and 1x1 Meetings

Interested parties can register for and access the live webcasts for these conferences by visiting the “” section of the Rani Therapeutics website. The webcast replays will be available after the conclusion of the respective presentations.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.

Investor Contact:

Media Contact:



EN
07/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RANI THERAPEUTICS HLDGS INC

 PRESS RELEASE

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provid...

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update - Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting transenteric delivery of GLP-1 incretin triagonist - - Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate in 2025 - SAN JOSE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RA...

 PRESS RELEASE

Rani Therapeutics to Participate in Upcoming Investor Conferences

Rani Therapeutics to Participate in Upcoming Investor Conferences SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s management team will participate in three upcoming conferences. These conferences include: UBS Global Healthcare Conference Location: Terranea Resort, Rancho Palos Verdes, CADate: Thursday, November 14, 2024 at 10:15am PTFormat: Fireside Chat and 1x1 Meetings S...

 PRESS RELEASE

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Suppo...

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist -Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and bioavailability comparable to subcutaneous injection - - New pharmacokinetic data provides further evidence of the RaniPill platform’s potential to enable oral delivery of multiple obesity treatments - - Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity, expected to initiate ...

 PRESS RELEASE

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Re...

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants SAN JOSE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,000,000 shares of Rani Therapeutics’ Class A common stock (the “Common Stock”) and pre...

 PRESS RELEASE

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual ...

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit SAN JOSE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) --  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024 from 11:30 am – 12:00 pm E.T. in Track 2. Interested parties ca...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch